Stable Micronized Vaccines Against Smallpox and Japanese Encephalitis

针对天花和日本脑炎的稳定微粉化疫苗

• 批准号: 7134299
• 负责人: Victor Bronshtein
• 金额: $ 43.15万
• 依托单位: UNIVERSAL STABILIZATION TECHNOLOGIES
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-08-15 至 2009-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7134299
• 关键词: encephalitis; temperature

DESCRIPTION (provided by applicant): Smallpox was one of the most important causes of morbidity and mortality worldwide through the first half of the 20th Century. Smallpox is a potential agent of bioterrorism; it has been designated as Category A Priority Pathogen. Despite the declaration of smallpox eradication in 1980, the existence of variola stockpiles and the threat of bioterrorism demand that immunity to smallpox through vaccination be maintained. In recent years, mosquito-borne infections are reemerging or emerging worldwide at an alarming rate. Japanese Encephalitis is a potential agent of bioterrorism; it has been designated as Category C Priority Pathogen. There are no licensed antiviral drugs against JE and only experimental treatments exist for smallpox. Therefore, vaccination and vector control are the only effective preventive tools, with vaccination being the most cost-effective strategy. Because of this effective protection of people requires immediate application of the countermeasures against these pathogens. Therefore, local storage of the countermeasures is preferable to ensure the greatest efficiency in combating the pathogens and to rapidly stop their spread. The best scenario could be achieved if local health professionals and emergency personal had convenient locally available supplies of vaccines that obviate the need for cold to ensure stability during storage. In the past few years, one of our two collaborating groups, the Group of Dr. Thomas Monath at Acambis has developed a new vaccine against Smallpox (Modified Vaccinia Ankara (MVA) and Japanese Encephalitis (ChimeriVax-JE live, attenuated chimeric vaccine). Both products are in clinical development under Food and Drug Administration (FDA) approved INDs. Both are live, attenuated vaccines and as such are susceptible to thermal degradation; hence, the vaccines must be kept refrigerated. During the past few years, the second of our two collaborating groups, Universal Stabilization Technologies (LIST), under the direction of Dr. Victor Bronshtein, has developed exciting new technologies for stabilizing bacteria and other live products. These technologies eliminate the damaging effects of conventional freeze-drying and allow the preparation of a live product that is stable at ambient temperature, eliminating the need for a cold chain. The objective of this grant proposal is to apply the novel technologies for stabilization developed at LIST to the manufacture of micronized ambient temperature stable MVA smallpox vaccine and ChimeriVax JE vaccine. Such formulated vaccines potentially could be delivered without need for reconstitution using transdermal, oral, nasal or inhalation delivery routes. During the first year our target will be vaccines that maintain high viability and potency after drying and subsequent storage at ambient temperatures. Working in collaboration, the Acambis and LIST will culture the vaccines, explore various ambient temperature stabilization approaches, confirm the stability and potency of the preserved vaccine, and test the immunogenicity and efficacy of the preserved vaccine using the mouse model.

描述(申请人提供)：在20世纪上半叶，天花是全世界发病和死亡的最重要原因之一。天花是潜在的生物恐怖主义病原体；它已被指定为A类优先病原体。尽管1980年宣布根除天花，但天花储存的存在和生物恐怖主义的威胁要求通过接种疫苗保持对天花的免疫力。近年来，蚊子传播的感染在全球范围内以惊人的速度重新出现或出现。乙型脑炎是一种潜在的生物恐怖主义病原体，已被指定为C类优先病原体。目前还没有获得许可的治疗乙脑的抗病毒药物，只有实验性的治疗天花的方法存在。因此，接种疫苗和病媒控制是唯一有效的预防手段，接种疫苗是最具成本效益的战略。正因为如此，要有效地保护人们，就需要立即针对这些病原体采取对策。因此，最好是在当地储存对策，以确保最大限度地有效地抗击病原体，并迅速阻止其传播。如果当地卫生专业人员和急救人员能够在当地方便地获得疫苗供应，以避免寒冷以确保储存期间的稳定性，则可以实现最佳情况。在过去的几年里，我们的两个合作小组之一，Acambis的Thomas Monath博士小组开发了一种新的天花疫苗(改良安卡拉疫苗(MVA)和日本脑炎(ChimeriVax-JE)活疫苗，减毒嵌合疫苗)。这两种产品都在食品和药物管理局(FDA)批准的INDS下进行临床开发。这两种疫苗都是减毒活疫苗，因此容易热降解；因此，疫苗必须冷藏。在过去的几年里，我们两个合作小组中的第二个，通用稳定技术(LIST)，在Victor Bronshtein博士的指导下，开发了令人兴奋的稳定细菌和其他活产品的新技术。这些技术消除了传统冷冻干燥的破坏性影响，并允许制备在环境温度下稳定的活产品，从而消除了对冷链的需要。这项赠款提案的目的是将LIST开发的稳定的新技术应用于微粉化常温稳定的MVA天花疫苗和ChimeriVax乙脑疫苗的生产。这种配方疫苗有可能在不需要重建的情况下使用经皮、口服、鼻腔或吸入给药途径提供。在第一年，我们的目标将是在干燥和随后在常温下储存后保持高活性和效力的疫苗。Acambis和List将合作培养疫苗，探索各种环境温度稳定方法，确认保存的疫苗的稳定性和效力，并使用小鼠模型测试保存的疫苗的免疫原性和效力。